We’re still funding-constrained with respect to how many researchers we’re likely to trial, as described above  but it now seems clear that 2016 overall won’t be an unusually bad year for us funding-wise, and that we can seriously consider (though not take for granted) more optimistic growth possibilities over the next couple of years.